Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06126003 | Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer. | terminated | — | 2 | BioCorteX IncINDUSTRY | 1 | Aug 2, 2024 |
| clinicaltrials |
| NCT04395339 | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction(GLORY) | terminated | Phase 3 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05239663 | GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer | terminated | Phase 3 | 76 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05068726 | Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients | terminated | — | 51 | GE HealthcareINDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06084676 | Organoid Model Predictive of Response to Immunotherapies | terminated | — | 1 | Indiana UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | terminated | N/A | 24 | Washington University School of MedicineOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin | terminated | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03393741 | Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy | terminated | — | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT00358098 | Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer | terminated | — | 51 | AHS Cancer Control AlbertaOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT04862143 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant(TELEPIK) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | terminated | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05163223 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer(Cornerstone001) | terminated | Phase 2 | 10 | Aston Sci. Inc.INDUSTRY | 2 | Jun 17, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 12, 2024 | clinicaltrials |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | terminated | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT01881880 | Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging | terminated | N/A | 424 | University Hospital, MontpellierOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | terminated | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04815291 | Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc ) | terminated | N/A | 93 | Merit Medical Systems, Inc.INDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | terminated | Phase 3 | 26 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT04655573 | A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer | terminated | — | 7 | Duke UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT01199367 | Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 11 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | terminated | Phase 3 | 1 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04469205 | Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer(OPTICOACH) | terminated | N/A | 69 | Institut CurieOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | terminated | Phase 2 | 3 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | terminated | Early Phase 1 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01616758 | Phase II Study of GTx024 in Women With Metastatic Breast Cancer | terminated | Phase 2 | 22 | GTxINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer(VERU-024) | terminated | Phase 3 | 5 | Veru Inc.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05458427 | Dedicated Breast CT for Diagnosis of Breast Cancer | terminated | — | 210 | Radboud University Medical CenterOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04927481 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer | terminated | Phase 2 | 28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04995575 | Dissecting the Pathways of Therapy Resistance in Early Breast Cancer(MINDACTRelapse) | terminated | — | 31 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT05236387 | Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection | terminated | — | 14 | Johns Hopkins UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT00984490 | Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery | terminated | N/A | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01956552 | Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE) | terminated | N/A | 130 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer(ARTEST) | terminated | Phase 3 | 52 | Veru Inc.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT05489679 | A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04947917 | Axillary Lymph Node Tattoo Marking Study | terminated | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | terminated | N/A | 1 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2024source: clinicaltrials